Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI)The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.
